Chunrui Li, MD, PhD, is a Chief Physician, Professor, and Doctoral Supervisor in the Department of Hematology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, and serves as Deputy Director of the department. Dr. Li’s clinical and translational work focuses on plasma cell disorders—particularly multiple myeloma—and cellular immunotherapy for hematologic malignancies. Dr. Li is the principal investigator for multiple CAR-T clinical trials, including studies related to an approved BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. Dr. Li’s team integrates clinical investigation with mechanistic research, using advanced technologies to characterize CAR-T cell kinetics, determinants of response, and mechanisms of resistance and relapse. Dr. Li has led projects funded by the National Natural Science Foundation of China (NSFC), delivered oral presentations at major international meetings (ASH, EHA, ASCO, IMW), and published more than 70 SCI-indexed papers. Dr. Li also holds positions in national and provincial hematology and myeloma societies and serves on editorial boards of hematology journals.